DOAC treatment outcomes for cerebral venous thrombosis in Vietnam

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, single-arm observational cohort conducted at Bach Mai Hospital, a national tertiary stroke referral center in Hanoi. At least 69 adults with radiologically confirmed cerebral venous thrombosis who received therapeutic-dose heparin acutely and are transitioned to dabigatran or rivaroxaban between days 5 and 15 will be enrolled and followed for 6 months. All treatments are prescribed as part of routine care and no investigational drugs are used; participants will have scheduled clinical visits, laboratory testing (including serial D-dimer), and neuroimaging to document outcomes. The primary outcome is a composite of major bleeding or recurrent venous thromboembolism within 6 months, with secondary outcomes including functional status (mRS), venous sinus recanalization, mortality, quality of life, and other safety endpoints.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Signed informed consent (ICF) to participate in the study
* Age ≥ 18 years
* Confirmed diagnosis of cerebral venous thrombosis (CVT) based on clinical presentation and neuroimaging, including one or more of the following:

MRI and MRV, AND/OR CT and CTV, AND/OR MRI or CT combined with DSA

* Initiation of DOACs within the first 15 days after starting treatment with heparin

Exclusion Criteria:

* CVT accompanied by antiphospholipid syndrome with all three positive laboratory criteria: lupus anticoagulant, anticardiolipin antibodies, and anti-β2-glycoprotein antibodies
* CVT in pregnant patients requiring continuous anticoagulation throughout pregnancy
* CVT with coexisting bleeding disorders, including immune thrombocytopenia with platelet count \<100,000/mL, hemophilia A or B, von Willebrand disease, or a history of prolonged bleeding after surgery or invasive procedures
* CVT in patients with mechanical heart valves, atrial fibrillation, and moderate to severe mitral stenosis
* CVT in patients with a glomerular filtration rate (GFR) \<15 mL/min
* CVT with severe hepatic impairment
* Patients already receiving anticoagulation therapy for another underlying condition at the time of CVT diagnosis

Where it's running

• Bach Mai Hospital
  Hanoi, Hanoi, Vietnam Recruiting

Study contacts

• Study coordinator: Hieu T. Dinh, MD
• Email: dr.dinhhieu1092@gmail.com
• Phone: +84982591092

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Danang Cerebral Venous Thrombosis Registry

  This registry collects information on adults with cerebral venous thrombosis admitted to Danang Hospital to see how the condition presents, what imaging shows, risk factors, and how patients recover.

  Recruiting Da Nang Hospital · Da Nang, Da Nang · NCT07890675

• Anticoagulation Plus Tocilizumab for Acute Cerebral Venous Thrombosis

  This study tests whether adding a single dose of tocilizumab to standard blood thinners helps people with acute cerebral venous thrombosis.

  Recruiting Capital Medical University · Beijing, Beijing Municipality · NCT07801638

• Anticoagulation plus batroxobin for acute cerebral venous thrombosis

  This trial tests whether adding batroxobin to standard anticoagulation helps adults with acute cerebral venous thrombosis.

  Recruiting Phase 4 Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT07352358

• Evaluating the safety and effectiveness of edoxaban and rivaroxaban for treating cerebral venous thrombosis in Chinese patients

  This study is testing whether two blood thinners, edoxaban and rivaroxaban, are safe and effective for treating cerebral venous thrombosis in Chinese patients aged 18 to 80.

  Recruiting Xuanwu Hospital, Beijing · Beijing, Beijing Municipality · NCT06947707

• Using direct oral anticoagulants to treat cerebral venous thrombosis

  This study is testing whether a new type of blood thinner called direct oral anticoagulants can safely and effectively treat people with cerebral venous thrombosis.

  Recruiting Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam, North Holland · NCT04660747

• Endovascular treatment plus anticoagulation for severe CVST in the MENA region

  This trial tests whether adding endovascular thrombectomy to standard anticoagulation helps adults with severe cerebral venous sinus thrombosis see better outcomes.

  Recruiting at 8 sites Middle East North Africa Stroke and Interventional Neurotherapies Organization · Alexandria and 13 other locations · NCT07548346

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.